This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Hait, W. N. Articles by Pierson, N. R. Search for Related Content PubMed PubMed Citation Articles by Hait, W. N. Articles by Pierson, N. R.

Comparison of the Efficacy of a Phenothiazine and a Bisquinaldinium Calmodulin Antagonist against Multidrug-resistant P388 Cell Lines¹

Departments of Medicine and Pharmacology, Yale University School of Medicine, New Haven, Connecticut 06510

Dequalinium belongs to a group of cationic lipophilic drugs believed to be selectively cytotoxic to malignant cells of epithelial origin by virtue of their accumulation in mitochondria. In addition, they are potent inhibitors of calmodulin and, therefore, might sensitize multidrug-resistant cells to chemotherapeutic agents. We compared the responsiveness of multidrug-resistant cells to the effect of dequalinium with that to trifluoperazine, a potent phenothiazine inhibitor of calmodulin. In addition, we studied the effect of these drugs on the responsiveness of multidrug-resistant cell lines to doxorubicin. The effect of drugs on P388 murine leukemic cells was determined by cell counting, [³H]thymidine incorporation into DNA, or soft agar cloning. Drug accumulation was measured by fluorescence spectrophotometry. We found that multidrug-resistant lines were less sensitive than parental cell lines to the intrinsic growth inhibitory effects of dequalinium (IC₅₀, 4.4 versus 0.3 µM in multidrug-resistant and sensitive P388 cells, respectively), whereas they were equally sensitive as the parental line to the effects of trifluoperazine. Following a 3-h exposure of P388/doxorubicin-resistant cells to 0–100 µM doxorubicin with or without either 10 µM dequalinium or 10 µM trifluoperazine, the latter increased the sensitivity to doxorubicin whereas the former had little effect (IC₅₀ values were doxorubicin, 30 µM; doxorubicin plus dequalinium, 25 µM; doxorubicin plus trifluoperazine, 4 µM).

Calmodulin prepared from resistant cells were equally sensitive to inhibition by dequalinium and trifluoperazine. P388/doxorubicin-resistant cells accumulated 4.5-fold less dequalinium than P388 cells whereas trifluoperazine was accumulated equally in both. The addition of 4 µM trifluoperazine to resistant cells exposed to 0–100 µM dequalinium completely reversed the alteration in accumulation and resistance to the dequalinium. These studies demonstrate that certain multidrug-resistant lines are cross-resistant to dequalinium and that sensitivity can be completely restored by nontoxic concentrations of trifluoperazine. The resistance appears to be due to changes in drug accumulation and not to be related to an altered sensitivity of calmodulin.

¹ Supported by the National Cancer Institute (Grants CA43888 and CA08341) and a grant from the American Cancer Society (CH-49507). Dr. Hait is a Burroughs Wellcome Scholar in Clinical Pharmacology. This work was presented in part at the American Association of Cancer Research, New Orleans, Louisiana, 1988.

² To whom requests for reprints should be addressed, at Department of Medicine, Yale University School of Medicine, 333 Cedar St., New Haven, CT 06510.

Received 2/ 9/89. Revised 5/12/89. Revised 8/28/89. Revised 11/ 6/89. Accepted 11/ 9/89.